)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Acrivon Therapeutics (ACRV) investor relations material
Acrivon Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Advanced ACR-368 (Phase 2 for endometrial cancer) and ACR-2316 (Phase 1 for solid tumors), leveraging the AP3 platform for accelerated drug development.
ACR-368 OncoSignature test received FDA Breakthrough Device and Fast Track designations; Phase 2 trial showed 35% confirmed ORR and 80% tumor shrinkage in OncoSignature-positive endometrial cancer patients.
No revenue generated to date; operations funded by equity offerings, including a $123.8M PIPE in April 2024.
Cash, cash equivalents, and investments totaled $147.6M as of June 30, 2025, expected to fund operations into Q2 2027.
AP3 platform presented at AACR 2025, highlighting new cell cycle program and drug mechanism insights.
Financial highlights
Net loss of $21.0M for Q2 2025, up from $18.8M in Q2 2024; net loss of $40.7M for the six months ended June 30, 2025.
Research and development expenses were $16.2M in Q2 2025 (up $1.2M year-over-year) and $31.6M for the six months (up $5.1M year-over-year).
General and administrative expenses were $6.5M in Q2 2025 and $12.7M for the six months, both nearly flat year-over-year.
Interest income for Q2 2025 was $1.7M, down from $2.7M in Q2 2024.
Net cash used in operating activities was $36.1M for the six months ended June 30, 2025.
Outlook and guidance
Cash and investments expected to fund operations and capital expenditures into Q2 2027; additional funding needed for long-term plans.
Anticipates continued increases in R&D and G&A expenses as clinical programs advance and headcount grows.
Plans to provide clinical data updates for ACR-368 and ACR-2316 in H2 2025.
Advancement of a new cell cycle drug discovery program toward candidate nomination in 2025.
Discuss the rationale for ULDG with ACR-368.
Elaborate on ACR-2316's target engagement.
Detail the undisclosed cell cycle target program.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Acrivon Therapeutics earnings date
Q3 20257 Nov, 2025
Next Acrivon Therapeutics earnings date
Q3 20257 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines. Utilizing its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, the company advances drug candidates tailored to the predicted sensitivity of tumors to specific medicines. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage